Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 15/20 | 1.00 |
| ▸ | INSR | P06213 | 8/20 | 1.00 |
| ▸ | LCK | P06239 | 3/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 3/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 3/20 | 1.00 |
| ▸ | AURKA | O14965 | 2/20 | 1.00 |
| ▸ | IKBKB | O14920 | 1/20 | 1.00 |
| ▸ | CHUK | O15111 | 1/20 | 1.00 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 1.00 |
| ▸ | PAK3 | O75914 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | FES | P07332 | 1/20 | 1.00 |
| ▸ | HCK | P08631 | 1/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 1/20 | 1.00 |
| ▸ | INSRR | P14616 | 1/20 | 1.00 |
| ▸ | FER | P16591 | 1/20 | 1.00 |
| ▸ | FLT4 | P35916 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29391496 | 1.00 | IGF1R (1.00) | IGF1RINSRLCKMAPK14AURKB | |
| SCHEMBL311108 | 0.98 | IGF1R (0.97) | IGF1RINSRLCKMAPK14AURKB | |
| SCHEMBL310484 | 0.97 | IGF1R (1.00) | IGF1RINSRLCKMAPK14AURKB | |
| SCHEMBL13226237 | 0.96 | IGF1R (0.92) | IGF1RINSRLCKMAPK14AURKB | |
| SCHEMBL310393 | 0.95 | IGF1R (1.00) | IGF1RINSRLCKMAPK14AURKB | |
| SCHEMBL310380 | 0.94 | IGF1R (1.00) | IGF1RINSRLCKMAPK14AURKB | |
| SCHEMBL310581 | 0.94 | IGF1R (0.88) | IGF1RINSRLCKMAPK14AURKB | |
| SCHEMBL310575 | 0.90 | IGF1R (0.88) | IGF1RINSRLCKMAPK14AURKB | |
| SCHEMBL310192 | 0.90 | IGF1R (0.95) | IGF1RINSRLCKMAPK14AURKB | |
| SCHEMBL310555 | 0.90 | EGFR (0.85) | IGF1RINSRLCKMAPK14AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2162454-B1 | IMIDAZOPYRIDINE KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-01-02 | — | — | EP | claimed |
| US-8093239-B2 | Imidazopyridine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-01-10 | — | — | US | claimed |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2010-08-26 | — | — | US | claimed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | claimed |
| US-20230270851-A1 | METHODS FOR THE TREATMENT OF IDIOPATHIC ORBITAL INFLAMMATION AND RELATED CONDITIONS | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2023-08-31 | — | — | US | disclosed |
| US-20230270851-A1 | METHODS FOR THE TREATMENT OF IDIOPATHIC ORBITAL INFLAMMATION AND RELATED CONDITIONS | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2023-08-31 | — | — | US | disclosed |
| WO-2023152337-A1 | AN IGF1R INHIBITOR AND AN AKT INHIBITOR FOR USE IN THE TREATMENT OF CANCER | GENOME RESEARCH LIMITED (GB) | 2023-08-17 | — | — | WO | disclosed |
| US-20210253719-A1 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2021-08-19 | — | — | US | disclosed |
| US-20210253686-A1 | METHODS FOR THE TREATMENT OF SCLERODERMA AND RELATED CONDITIONS | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2021-08-19 | — | — | US | disclosed |
| US-10064939-B2 | Combination therapy using c-Met inhibitor and IGF-1R inhibitor for c-Met inhibitor resistant cancers | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2018-09-04 | — | — | US | disclosed |
| US-10004735-B2 | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines | SIGNAL PHARMACEUTICALS, LLC (US) | 2018-06-26 | — | — | US | disclosed |
| US-9943596-B2 | Combination therapy using dual inhibitor of c-MET and EGFR and IGF-1R inhibitor | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2018-04-17 | — | — | US | disclosed |
| US-8093239-B2 | Imidazopyridine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2010-08-26 | — | — | US | disclosed |
| WO-2008150799-A1 | IMIDAZOPYRIDINE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | ABL1, MAP3K19, MAP3K5 | IGF1R 633/4885INSR 814/4885LCK 49/4885 |
| US-20230270851-A1 | METHODS FOR THE TREATMENT OF IDIOPATHIC ORBITAL INFLAMMATION AND RELATED CONDITIONS | IGF1R, IGFBP1, IRS1 | IGF1R 1/4885INSR 9/4885LCK 3056/4885 |
| US-20210253719-A1 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | TPO, TSHR, TRHDE | IGF1R 916/4885INSR 1159/4885LCK 1101/4885 |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | ABL1, MAP3K19, MAP3K5 | IGF1R 633/4885INSR 814/4885LCK 49/4885 |
| US-10064939-B2 | Combination therapy using c-Met inhibitor and IGF-1R inhibitor for c-Met inhibitor resistant cancers | MET, IGF1R, IGFBP1 | IGF1R 2/4885INSR 22/4885LCK 2410/4885 |
| US-10004735-B2 | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines | MTOR, ULK2, TTK | IGF1R 1058/4885INSR 3486/4885LCK 449/4885 |
| US-20210253686-A1 | METHODS FOR THE TREATMENT OF SCLERODERMA AND RELATED CONDITIONS | IGF1R, IGFBP1, IGFBP2 | IGF1R 1/4885INSR 20/4885LCK 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.